Ratings by JPMorgan (Ekaterina Knyazkova)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 9/24/2025 | ANI Pharmaceuticals | ANIP | Maintain | Overweight (Overweight) |
|
Details | ||
| 8/11/2025 | ANI Pharmaceuticals | ANIP | Maintain | Overweight (Overweight) |
|
Details | ||
| 7/7/2025 | Phibro Animal Health Corp. | PAHC | Upgrade | Overweight (Neutral) |
27.94 (34.65) |
24.02% | Details | |
| 5/12/2025 | Amphastar Pharmaceuticals | AMPH | Downgrade | Neutral (Overweight) |
24.65 (21.34) |
-13.43% | Details | |
| 3/12/2025 | ANI Pharmaceuticals | ANIP | New Coverage | Overweight (N/A) |
58.81 (76.87) |
30.71% | Details | |
| 2/14/2025 | Amphastar Pharmaceuticals | AMPH | Maintain | Overweight (Overweight) |
|
Details | ||
| 9/10/2024 | Phibro Animal Health Corp. | PAHC | New Coverage | Neutral (N/A) |
19.46 (27.94) |
43.58% | Details | |
| 3/5/2024 | Amphastar Pharmaceuticals | AMPH | New Coverage | Overweight (N/A) |
46.22 (24.65) |
-46.67% | Details |
